We’d like to extend our congratulations to Dr. Michael Rosenberg, our CEO and resident author, on the release of his new book: The Agile Approach to Adaptive Research: Optimizing... Read more
In a recent Wall Street Journal column , Thomas Friedman presents an interesting take on the Chinese economy, which brings to mind an interesting parallel with the drug development industry. He... Read more
After a year of legislation and congressional speculation insulating medical device makers from lawsuits and economic penalties, it looks as though the FDA will replace its favor with the same... Read more
A recent article (originally appearing in Oncology NEWS International Vol. 18 No. 12) discusses traditional Phase II trials for oncology and whether or not they should be phased out. The author... Read more
We recently got a chance to chat with Applied Clinical Trials’ Lisa Henderson about our new network approach to global clinical development. Coming face to face with breaking industry... Read more
At the Fourth Annual Site Solutions Summit in October , 150 site stakeholders and two dozen sponsors and CROs achieved consensus on six site best practices. Organizers of the event said if... Read more
The whole country has its ear turned toward Washington, eagerly listening for how we’ll be affected by the myriad proposed disruptions to healthcare policy. Notwithstanding the legitimate... Read more
The Triangle Business Journal reported yesterday that scientists from the BC Cancer Agency have decoded the DNA of metastatic lobular breast cancer, which accounts for about 10 percent of all... Read more
From the current issue of Bio-IT World comes yet another report on the growing frustration with EDC systems and their failure to deliver on promised efficiencies: ”Of all the e-clinical... Read more
The difficulty of getting oncology products to market was emphasized in a recent New York Times article , along with a good lesson about needlessly risky study execution. The article... Read more
